U.S. Markets open in 4 hrs 24 mins
  • S&P Futures

    3,777.50
    -12.00 (-0.32%)
     
  • Dow Futures

    30,680.00
    -101.00 (-0.33%)
     
  • Nasdaq Futures

    11,491.25
    -38.25 (-0.33%)
     
  • Russell 2000 Futures

    1,700.30
    -7.70 (-0.45%)
     
  • Crude Oil

    107.31
    +1.55 (+1.47%)
     
  • Gold

    1,793.30
    -14.00 (-0.77%)
     
  • Silver

    19.72
    -0.63 (-3.11%)
     
  • EUR/USD

    1.0464
    -0.0020 (-0.1883%)
     
  • 10-Yr Bond

    2.9720
    0.0000 (0.00%)
     
  • Vix

    28.87
    +0.71 (+2.52%)
     
  • GBP/USD

    1.2110
    -0.0065 (-0.5317%)
     
  • USD/JPY

    135.5630
    -0.1650 (-0.1216%)
     
  • BTC-USD

    19,540.62
    +312.95 (+1.63%)
     
  • CMC Crypto 200

    420.60
    -10.87 (-2.52%)
     
  • FTSE 100

    7,180.27
    +10.99 (+0.15%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

HAMILTON, ON and BOSTON, Jan. 21, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the B. Riley Securities 2022 Virtual Oncology Conference on Thursday, January 27, 2022 at 2:00 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

(PRNewsfoto/Fusion Pharmaceuticals Inc.)
(PRNewsfoto/Fusion Pharmaceuticals Inc.)

A webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-b-riley-securities-2022-virtual-oncology-conference-301465560.html

SOURCE Fusion Pharmaceuticals Inc.